CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...
On June 28, 2012, the most significant scientific breakthrough of the first quarter of the 21st century was announced to the ...
Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...
With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...
That’s why a team from UC San Diego in La Jolla set out with Yale University researchers to develop a new system for gene editing that they believe may be safer and more efficient than the common ...
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has ...
The idea that a single-celled bacterium can defend itself against viruses in a similar way as the 1.8-trillion-cell human immune system is still “mind-blowing” for molecular biologist Joshua Modell of ...
STAT has twice been named a Pulitzer Prize finalist and has won a number of prestigious journalism prizes, including the George Polk Awards, Victor Cohn Prize for Excellence in Medical Science ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback